+44 20 8123 2220
info@marketpublishers.com

T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019

https://marketpublishers.com/r/T986BD63C6F3EN.html
Date: December 2019
Pages: 88
Price: US$ 3,500.00 (Single User License)
ID: T986BD63C6F3EN

Abstracts

T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019

SUMMARY

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.

T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology, Respiratory and Undisclosed which include indications Rheumatoid Arthritis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Cytopenia, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Immunoglobulin G4-Related Disease (IgG4-RD), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Kidney Transplant Rejection, Lupus Nephritis, Melanoma, Myasthenia Gravis, Nephrotic

+44 20 8123 2220
info@marketpublishers.com

Syndrome, Non-Small Cell Lung Cancer, Polymyalgia Rheumatica (PMR), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Unspecified, Uveitis and Vitiligo.

The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

+44 20 8123 2220
info@marketpublishers.com

targeted therapeutics and enlists all their major and minor projects

The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape

+44 20 8123 2220
info@marketpublishers.com

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Dec 05, 2019: BMS' Orencia gets breakthrough status in US to prevent GvHD
Nov 07, 2019: Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting
Jun 13, 2019: New mechanistic study explores the relationship between a key genetic marker and clinical efficacy of ORENCIA (abatacept) or adalimumab in moderate-to-severe early Rheumatoid Arthritis patients
Mar 11, 2019: BMSKK and ONO submit supplemental applications of Orencia for I.V. infusion, Orencia Syringe for S.C. Injection and Orencia Autoinjector for S.C. Injection, a selective T-cell co-stimulation modulator, for inhibition of structural damage of joints in Rheumatoid Arthritis
Feb 27, 2019: BioAtla presents CAB-CTLA-4 program BA3071 data at The American Association For Cancer Research Annual Meeting
Jan 31, 2019: CHMP recommended extension of indication for Orencia
Oct 17, 2018: Bristol-Myers Squibb to showcase immunoscience research and biomarker-guided treatment approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jun 13, 2018: Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Feb 23, 2018: Orencia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan
Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Nov 13, 2017: Bristol-Myers Squibb's Orencia Rejects For Use Within NHS Scotland
Nov 02, 2017: Bristol-Myers Squibb to Showcase Company's Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
Jul 26, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis
Jul 06, 2017: Bristol-Myers Squibb's ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

COMPANIES MENTIONED

Adagene (Suzhou) Ltd
Alphamab Oncology
AstraZeneca Plc
BioAtla LLC
Bristol-Myers Squibb Co
Cue Biopharma Inc
GeneFrontier Corp
GI Innovation Co Ltd

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2019
Product link: https://marketpublishers.com/r/T986BD63C6F3EN.html
Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/T986BD63C6F3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970